Funding & VC

VitriVax Closes $87M Series C to Push Lyme Vaccine Into Human Trials

VitriVax raised an oversubscribed $87M Series C led by F-Prime, NEA, RA Capital and Sanofi Ventures to take its single-dose Lyme disease vaccine candidate into first-in-human trials.

By Amara Osei

3 min read

VitriVax Raises $87 Million To Advance Lyme Disease Vaccine
VitriVax Raises $87 Million To Advance Lyme Disease VaccineAI-generated

What's News

  • VitriVax closed an oversubscribed $87 million Series C, more than 5x its $17.25 million Series B.
  • F-Prime, NEA, RA Capital Management and Sanofi Ventures co-led; Eli Lilly also participated.
  • The lead candidate targets Lyme disease, for which no approved human vaccine exists today.
  • The ALTA platform enables single-dose vaccines and mRNA delivery without lipid nanoparticles.
  • Prior backers include the Gates Foundation, CEPI and the U.S. Department of Defense.

VitriVax has closed an oversubscribed $87 million Series C to move its Lyme disease vaccine candidate into a first-in-human clinical trial. F-Prime, NEA, RA Capital Management and Sanofi Ventures co-led the round. Eli Lilly and existing investors also participated.

The financing is more than five times the size of the company's previous raise, a $17.25 million Series B. VitriVax has also drawn support from the Gates Foundation, CEPI and the U.S. Department of Defense.

What makes the Lyme candidate different?

The lead program is built to deliver broad protection against Lyme disease through a new mechanism. That matters because there is currently no approved human vaccine for Lyme disease at all, and rival candidates in development require multiple initial doses plus seasonal boosters.

The candidate sits on VitriVax's ALTA platform — Atomic Layering Thermostable Antigen and Adjuvant. The technology is designed to do four things:

  • Enable single-dose vaccines
  • Improve immune responses
  • Cut the quantities of antigen and adjuvant required
  • Reduce dependence on refrigerated distribution

VitriVax has also applied the platform to mRNA delivery without lipid nanoparticles — a notable extension beyond conventional protein-based shots.

CEO Romulo Colindres framed the round as an inflection point. "The strong demand for this financing round and the caliber of investors who joined it reflect growing conviction in our ALTA platform and in our Lyme disease vaccine candidate," he said. "This financing marks VitriVax's transition into a vaccine development company with its own pipeline."

He added: "Our priorities now are to generate first-in-human data for our Lyme disease candidate, and build a portfolio of proprietary programs, while continuing our work with global health partners to bring better vaccines to the people who need them most."

Why the investors wrote the check

The co-leads each put their own thesis on the record. Chris Gagliardi, Principal at Sanofi Ventures, pointed to the platform's breadth: "VitriVax's ALTA platform brings together several compelling capabilities into one differentiated approach, and we are excited to support the team as they advance the technology and explore its potential across a broader range of applications."

Mario Barro, Head of Infectious Diseases and Venture Partner at RA Capital, stressed the unmet need. "We need a safe, effective, and convenient Lyme vaccine to prevent millions of people from suffering the dangerous, chronic, and painful ramifications of this increasingly common disease," he said. He called ALTA "a potentially game-changing technology across protein/glycoconjugate and mRNA modalities."

Muzammil Mansuri, Venture Partner at F-Prime, highlighted logistics rather than biology. "VitriVax's approach eliminates traditional barriers – complex dosing and cold chain hurdles – so more people can benefit," he said. "We are proud to support VitriVax as they advance practical solutions for patients and healthcare providers alike."

Where the money goes

VitriVax will deploy the $87 million on two fronts: generating initial clinical data for the Lyme candidate and building additional wholly owned programs on the ALTA platform. The company isn't specifying timelines for the first-in-human trial.

The round lands as Lyme disease grows more common and the vaccine field remains empty on the human side. With Big Pharma money now at the table — Sanofi Ventures and Eli Lilly both bought in — the next milestone investors will watch is the first clinical safety and immunogenicity readout from the Lyme program.

Source: pulse2.com

Share this article:

More from Amara Osei

Amara Osei

Show full bio

Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.

2,398 articles

Related articles

« Previous article